Category: Latest News
-
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial
Oruka Therapeutics Inc (NASDAQ:ORKA) saw its stock rise 6.6% after revealing that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application to begin a Phase 2a clinical trial of its psoriasis drug, ORKA-001. The study, named EVERLAST-A, will test Oruka’s extended-duration anti-IL-23p19 antibody in roughly 80 patients suffering from…
-
Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD). The hold impacts a series of Sarepta’s experimental therapies, including SRP-9003, SRP-9004, SRP-6004, and SRP-9005. Notably, Sarepta…
-
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement
SAB Biotherapeutics Inc (NASDAQ:SABS) saw its stock surge by 33% following the announcement of a $175 million private placement backed by a mix of strategic and institutional investors. The oversubscribed financing round was led by pharmaceutical giant Sanofi (NASDAQ:SNY) and joined by new investors such as RA Capital Management, Commodore Capital, Vivo Capital, and Blackstone’s…
-
U.S. Stocks Edge Higher as Investors Watch Earnings and Tariff Developments
U.S. stocks moved up slightly on Monday morning as investors looked ahead to a busy week of second-quarter earnings reports, with major firms set to announce results. By 9:35 a.m. ET: Markets had stalled near record highs last Friday amid reports that President Trump is pushing for new tariffs of at least 15% to 20%…
-
Dow Jones, S&P, Nasdaq, Wall Street Set for Higher Open Amid Trade Optimism and Earnings Watch
U.S. markets are on track for a higher open Monday, as investors digest growing optimism surrounding trade negotiations and brace for a wave of major corporate earnings. Futures linked to the Dow Jones Industrial Average, Nasdaq, and S&P 500 are pointing toward early gains, rebounding from a muted close last Friday when stocks lacked direction…
-
Helius Medical Technologies Surges 70% on Promising Stroke Therapy Trial Results
July 21, 2025 — Helius Medical Technologies (NASDAQ:HSDT) saw its stock soar more than 70% in pre-market trading Monday after reporting strong clinical results for its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP). The neurotechnology company announced that a double-blind, randomized clinical trial for the PoNS SRP successfully met its primary endpoint. The trial…
-
DeFi Development Corp. stock surges as Solana holdings approach 1 million
Shares of DeFi Development Corp. (NASDAQ:DFDV) climbed 10.6% after the company revealed it is on the verge of holding 1 million Solana (SOL) tokens, with its balance now totaling 999,999 SOL and equivalents — a position worth approximately $181 million. Between July 14 and July 20, the firm acquired 141,383 SOL at an average cost…
-
Upexi shares rally as Solana holdings grow to $331 million
Shares of Upexi Inc. (NASDAQ:UPXI) jumped 14.3% after the company revealed it had expanded its position in Solana, acquiring an additional 100,000 SOL tokens. This latest purchase brings Upexi’s total Solana holdings to 1,818,809 SOL, valued at roughly $331 million. The newly acquired tokens, bought for $17.7 million, follow last week’s closing of a $200…
-
SS&C Technologies stock gains following $1.03B Calastone acquisition deal
Shares of SS&C Technologies Holdings Inc (NASDAQ:SSNC) climbed 3.1% after the company announced it has reached a definitive agreement to acquire Calastone, the world’s largest funds network, in a deal valued at roughly £766 million (US $1.03 billion). The seller is global investment firm Carlyle. The acquisition is projected to close in the fourth quarter…
-
Evotec shares drop sharply after lowering 2025 revenue forecast
Evotec SE ADR (NASDAQ:EVO) saw its stock decline 12.7% following a downward revision of its revenue guidance for fiscal year 2025, attributed to weaker-than-expected results in its Shared R&D base segment. The company now anticipates revenues between €760 million and €800 million, a reduction from its earlier forecast of €840 million to €880 million. This…